Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 218575 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Form and strength TABLET - 150MG Sponsor APOTEX INC Submission history Latest submission status date: 2026-02-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 218575 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE Form and strength TABLET - 150MG Sponsor APOTEX INC Submission history Latest submission status date: 2026-02-09 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.